Mallinckrodt Pharmaceuticals

Open-Label Expanded Access Treatment Protocol for VTS-270

.
Christopher Hitchens
email: christopher.hitchens@mnk.com | phone: 202-494-0788

Karrie Hilsinger
email: karrie.hilsinger@mnk.com | phone: 908-310-0135

CLINICALTRIALS.GOV LINK
_____________________________

Mallinckrodt Announces an Open-label

Expanded Access Treatment Protocol for VTS-270

.
CLICK HERE FOR COMPLETE ANNOUNCEMENT

08/27/2018 jjb

The National Niemann-Pick Disease Foundation (NNPDF) does not engage in the practice of medicine. It is not a medical authority nor does it claim to have medical knowledge. This site is an educational service of the National Niemann-Pick Disease Foundation and is not meant to provide diagnostic or treatment advice. Information contained or suggested on this Web site does not constitute medical advice. For all information related to care, medication or treatment, the NNPDF recommends consulting a physician to determine if information presented is applicable. Please review these additional cautions about medical information provided on the Internet.

This Web site is a service of the National Niemann-Pick Disease Foundation's Family Services Program, made possible by the financial support of our member families and other generous donors and grantors. This site receives no government funding, nor does it host or receive funding from advertising or from the display of commercial content.

The National Niemann-Pick Disease Foundation is a 501(c)(3) organization. Your donations are fully tax-deductible.

Mallinckrodt Pharmaceuticals

Open-Label Expanded Access Treatment Protocol for VTS-270

Mallinckrodt Announces an Open-label

Expanded Access Treatment Protocol for VTS-270

08/27/2018 jjb

Share this!